ClinicalTrials.gg
RecruitingNCT07673601Updated Jun 29, 2026

A Study to Assess the Absolute Bioavailability and How Adimanebart SC Moves Through the Body in Healthy Adult Participants

A Phase 1 interventional study of Adimanebart IV and Adimanebart SC - formulation A in Healthy Volunteers (HV) and Healthy Volunteer, sponsored by argenx. Recruiting at 1 site in Canada. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-29.

Sponsored by argenx · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Jun 2026; still recruiting 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
52
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

This study aims to find out how much adimanebart gets into the blood circulation of healthy adults. Researchers will measure the amount of adimanebart in blood over time to learn how it moves through the body. The drug's safety will also be assessed.

The participants will be assigned to one of 3 parts of the study: part 1 investigates the absolute bioavailability; part 2 investigates the effect of different body weights on adimanebart in blood after subcutaneous (SC) dosing; part 3 investigates formulation adaptations.

Participants will be in the study for approximately up to 24 weeks.

02

Conditions studied

  • Healthy Volunteers (HV)
  • Healthy Volunteer
03

In context

Lead sponsor

argenx is the lead sponsor of 87 studies on the registry; 28 are open to participants now.

Of its 22 completed or terminated interventional studies of FDA-regulated products, 16 (73%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Is at least the local legal age of consent and aged 18 to 65 years, inclusive, when signing the ICF.
  • Has a body weight between 60 and 100 kg and a between 18.5 and 30 kg/m2, inclusive, at screening and on day -1 for part 1 and part 3, or has a body weight \<60 kg or between 100 and 130 kg and a BMI between 18.5 and 38.0 kg/m2, inclusive, at screening and on day -1 for part 2.
  • Discontinues and refrains from using all medications, including nonprescription and prescription medications, for ≥2 weeks before IMP administration, except for hormonal and hormone replacement therapy in female participants. The occasional use of acetaminophen or ibuprofen is allowed.

Exclusion criteria

Exclusion Criteria:

  • Has any current or past medical or psychiatric condition, including severe reactions to drugs and/or food that, in the investigator's opinion, would confound the study results or put the participant at undue risk.
  • Previously participated in an adimanebart clinical study and received at least 1 dose of IMP.
  • Is currently participating in another interventional clinical study, or has received an IMP in another clinical study within 12 weeks or 5 half-lives (whichever is longer) before screening.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
52 participants (estimated)

Study arms

  • Experimental
    Part 1 - Adimanebart IV

    Participants randomized to receive adimanebart IV

    Biological: Adimanebart IV

  • Experimental
    Part 1 - Adimanebart SC (formulation A)

    Participants randomized to receive adimanebart SC

    Biological: Adimanebart SC - formulation A

  • Experimental
    Part 2 - Adimanebart SC (formulation A) in lower body weights

    Participants with body weight \< 60 kg will receive adimanebart SC

    Biological: Adimanebart SC - formulation A

  • Experimental
    Part 2 - Adimanebart SC (formulation A) in higher body weights

    Participants with body weight between 100 and 130 kg will receive adimanebart SC

    Biological: Adimanebart SC - formulation A

  • Experimental
    Part 3 - Adimanebart SC (formulation B)

    Participants randomized to receive adimanebart SC formulation B

    Biological: Adimanebart SC - formulation B

  • Experimental
    Part 3 - Adimanebart SC (formulation C)

    Participants randomized to receive adimanebart SC formulation C

    Biological: Adimanebart SC - formulation C

Interventions

  • BiologicalAdimanebart IV

    Intravenous infusion of adimanebart IV

  • BiologicalAdimanebart SC - formulation A

    Subcutaneous administration of Adminanebart SC

  • BiologicalAdimanebart SC - formulation B

    Subcutaneous administration of Adminanebart SC

  • BiologicalAdimanebart SC - formulation C

    Subcutaneous administration of Adminanebart SC

06

What researchers measure

Primary outcomes

  1. AUC0-inf

    AUC0-inf = area under the concentration-time curve from time 0 to infinity

    Time frame: Up to 20 weeks

Secondary outcomes

  1. adimanebart SC PK parameter: Cmax

    Cmax = maximum observed concentration

    Time frame: Up to 20 weeks

  2. Incidence of AEs, SAEs, and AEs leading to adimanebart discontinuation

    AE = adverse event ; SAE = serious adverse event

    Time frame: Up to 20 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2026 (actual). Primary completion is estimated for Dec 2026, 6 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 23, 2026
First posted
Jun 29, 2026
StartActual
Jun 12, 2026
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
Jun 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07673601
Lead sponsor
argenx
Responsible party
Sponsor
First posted
Jun 29, 2026
Start date
Jun 12, 2026
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Jun 29, 2026

Study contacts

Sabine Coppieters, MD
Contact
clinicaltrials@argenx.com
857-350-4834

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Adimanebart

Start the discussion